[Federal Register: September 2, 2003 (Volume 68, Number 169)] [Notices] [Page 52224-52225] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr02se03-107] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 22, 2003, Cambridge Isotope Laboratories, Inc., 50 Frontage Road, Andover, Massachusetts 01801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below: ------------------------------------------------------------------------ Drug Schedule ------------------------------------------------------------------------ Methaqualone (2565)........................ I Dimethyltryptamine (7435).................. I Amphetamine (1100)......................... II Methamphetamine (1105)..................... II Pentobarbital (2270)....................... II Secobarbital (2315)........................ II Phencyclidine (7471)....................... II Cocaine (9041)............................. II Codeine (9050)............................. I Oxycodone (9143)........................... II Hydromorphone (9150)....................... II Benzoylecgonine (9180)..................... II Methadone (9250)........................... II Dextropropoxyphene (9273).................. II Morphine (9300)............................ II [[Page 52225]] Fentanyl (9801)............................ II ------------------------------------------------------------------------ The firm plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug analysis. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than November 3, 2003. Dated: August 19, 2003. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 03-22328 Filed 8-29-03; 8:45 am] BILLING CODE 4410-09-M